Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
11,400
+220 (1.97%)
At close: Apr 2, 2026
KRX:007570 Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 23,654 | 4,295 | 3,414 | 7,174 | 9,288 |
Short-Term Investments | 5,973 | 8,495 | 10,276 | 5,419 | 34,111 |
Trading Asset Securities | - | - | - | - | 231.78 |
Cash & Short-Term Investments | 29,627 | 12,790 | 13,690 | 12,593 | 43,631 |
Cash Growth | 131.64% | -6.57% | 8.72% | -71.14% | 4.85% |
Accounts Receivable | 44,972 | 44,777 | 47,656 | 48,762 | 52,803 |
Other Receivables | 3,940 | 3,936 | 4,680 | 4,716 | 3,297 |
Receivables | 48,912 | 48,713 | 52,336 | 53,479 | 56,101 |
Inventory | 64,243 | 59,873 | 53,108 | 48,387 | 32,423 |
Prepaid Expenses | 651.12 | 158.02 | 186.42 | 303.23 | 515.3 |
Other Current Assets | 4,329 | 3,652 | 4,339 | 3,656 | 3,671 |
Total Current Assets | 147,762 | 125,187 | 123,659 | 118,418 | 136,340 |
Property, Plant & Equipment | 220,675 | 216,421 | 181,973 | 178,244 | 175,779 |
Long-Term Investments | 40,678 | 43,510 | 38,572 | 52,847 | 45,029 |
Other Intangible Assets | 1,712 | 1,888 | 1,826 | 1,935 | 2,078 |
Long-Term Deferred Charges | 24,039 | 23,453 | 25,530 | 29,481 | 34,392 |
Other Long-Term Assets | 22,464 | 20,568 | 21,046 | 21,991 | 25,643 |
Total Assets | 457,331 | 431,027 | 392,607 | 402,916 | 419,261 |
Accounts Payable | 20,704 | 22,322 | 26,307 | 29,813 | 23,717 |
Accrued Expenses | 480.55 | 513.8 | 398.44 | 310.58 | 314.19 |
Short-Term Debt | 96,216 | 92,505 | 65,789 | 71,000 | 92,500 |
Current Portion of Long-Term Debt | 3,333 | - | - | 2,000 | - |
Current Portion of Leases | 189.5 | 266.59 | 522.11 | 370.52 | 159.24 |
Current Income Taxes Payable | 236.4 | 1,293 | 1,126 | 958.54 | 3,542 |
Other Current Liabilities | 50,012 | 40,649 | 45,121 | 40,875 | 47,687 |
Total Current Liabilities | 171,172 | 157,549 | 139,263 | 145,328 | 167,920 |
Long-Term Debt | 26,667 | 14,700 | 6,000 | - | 5,000 |
Long-Term Leases | 388.51 | 209.38 | 339.24 | 732.69 | 843.73 |
Pension & Post-Retirement Benefits | 7,018 | 8,580 | 7,322 | 7,909 | 8,136 |
Long-Term Deferred Tax Liabilities | 8,227 | 8,565 | 9,233 | 10,662 | 10,464 |
Other Long-Term Liabilities | 2,450 | 1,891 | 50 | 500 | 21.5 |
Total Liabilities | 215,922 | 191,494 | 162,207 | 165,132 | 192,385 |
Common Stock | 47,714 | 47,714 | 47,714 | 47,714 | 47,714 |
Additional Paid-In Capital | 78,370 | 78,370 | 78,441 | 78,416 | 78,590 |
Retained Earnings | 122,790 | 118,759 | 53,559 | 58,759 | 43,170 |
Treasury Stock | -12,269 | -11,269 | -11,921 | -10,075 | -7,437 |
Comprehensive Income & Other | -114.37 | 1,264 | 57,957 | 58,496 | 60,587 |
Total Common Equity | 236,490 | 234,838 | 225,751 | 233,311 | 222,624 |
Minority Interest | 3,805 | 3,582 | 3,536 | 3,361 | 3,139 |
Shareholders' Equity | 241,409 | 239,533 | 230,400 | 237,785 | 226,876 |
Total Liabilities & Equity | 457,331 | 431,027 | 392,607 | 402,916 | 419,261 |
Total Debt | 126,794 | 107,681 | 72,650 | 74,103 | 98,503 |
Net Cash (Debt) | -97,168 | -94,891 | -58,960 | -61,511 | -54,872 |
Net Cash Per Share | -5277.21 | -5148.09 | -3272.13 | -3393.60 | -3014.10 |
Filing Date Shares Outstanding | 19.79 | 18.01 | 17.97 | 18.09 | 18.21 |
Total Common Shares Outstanding | 19.79 | 18.01 | 17.97 | 18.09 | 18.21 |
Working Capital | -23,410 | -32,362 | -15,604 | -26,910 | -31,580 |
Book Value Per Share | 11951.56 | 13036.87 | 12561.42 | 12899.45 | 12228.63 |
Tangible Book Value | 234,778 | 232,951 | 223,925 | 231,375 | 220,547 |
Tangible Book Value Per Share | 11865.05 | 12932.07 | 12459.79 | 12792.46 | 12114.49 |
Land | 118,556 | 120,507 | 120,298 | 120,308 | 116,955 |
Buildings | 39,558 | 41,126 | 42,787 | 44,474 | 45,995 |
Machinery | 2,994 | 4,055 | 6,060 | 9,367 | 9,480 |
Construction In Progress | 58,415 | 49,583 | 11,435 | 2,384 | 1,953 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.